Mitochondrial Disease

Coming Soon! Mitochondrial Disease Version 2.0 CDEs - March 2024

Data Standards

Organized by domains and subdomains often used in clinical studies, data standards include:

  • CDEs — Classified as Core, Supplemental–Highly Recommended, Supplemental, or Exploratory
  • CRF Modules — Template forms that logically organize CDEs for data collection
  • Guidance Documents — Provide further information about the CDEs
  • Instrument Notice of Copyright (NOC) Documents: Include pertinent information on recommended instruments (Instrument Notice of Copyright Information)

Mitochondrial Disease Start-up Resource Listing: All Core and Supplemental–Highly Recommended CDEs recommended for Mitochondrial Disease study start-up

Mitochondrial Disease Highlight Summary: Overview of all Mitochondrial Disease-specific CDE recommendations as they appear on the website

Click Expand All to view the CDEs associated with the CRF modules, organized by domain and subdomain

Form Search Instructions - Please Read Before Searching

The Form Search is designed to filter the CRF Modules, Guidance Documents, and NOCs on this page by Search Term, Domain, Subdomain, and/or Copyright Status. The Copyright field is designed to filter between forms that are freely available online and forms that are copyrighted or trademarked. Please note that regardless of copyright/trademark status, these instruments are not available on this website. All recommended instruments, regardless of copyright status, have informational documents posted on the NINDS CDE website which provide details concerning availability.

Helpful Hints:

Once you have completed your search, the search results will need to be expanded by clicking the Expand All button to view results.

The default setting for Domain, Subdomain and Copyright fields is ‘Any’.

Leave the Search Term(s) field blank to return all results or enter search terms or keywords to return any forms that match the terms that are entered.

For best results, click the Clear button between searches.

Please contact NINDS CDE team (NINDSCDE@emmes.com) in case you encounter any search difficulties.

Click here for additional instructions

Participant Characteristics
Demographics
CRF Module/Guidance CDEs
General Core CDE Details
Participant History and Family History
Outcomes and End Points
Academic Achievement
CRF Module/Guidance CDEs
American National Adult Reading Test (AmNART) N/A
Neuropsychological Testing
CRF Module/Guidance CDEs
Bayley Scales of Infant Development (Bayley III, BSID) N/A
Visual-Spatial Processing
CRF Module/Guidance CDEs
Judgment of Line Orientation (Benton JLO) N/A
Memory
CRF Module/Guidance CDEs
Memory Assessment Scale N/A
Pulmonary Function Testing/Respiratory Status
CRF Module/Guidance CDEs
Pulmonary Function CDE Details

Overview

The National Institute of Neurological Disorders and Stroke (NINDS) convened the Mitochondrial Disease v1.0 Common Data Elements (CDE) Working Group (WG) in 2014. The Mitochondrial Disease v1.0 CDE WG was divided into 9 domain-specific subgroups. The first set of CDEs for Mitochondrial Disease was completed in 2015.

The Mitochondrial Disease CDE Oversight Committee (OC) was created in 2018 to periodically review, direct the updating, and advance the development of Mitochondrial Disease CDEs.

In 2022, the Mitochondrial Diseases v2.0 CDE WG was convened to perform a comprehensive review and update of the Mitochondrial Disease v1.0 CDEs.

The WG used a common definition of primary mitochondrial diseases to help focus this review and standardize the recommendations: Mitochondrial Disease Definition.

The WG was divided into 11 domain-specific subgroups: Audiology Outcomes, Biomarkers, Cognitive/Psychological Outcomes, Endocrinology, Exercise Physiology, GI/Hepatology and Nutrition, General Medical/Neurological Assessments, Genetics, Imaging, Ophthalmology Outcomes, and Patient Reported Outcomes (PRO)/Quality of Life (QoL)/Fatigue.

The Internal Review and Public Review period for the draft Mitochondrial Disease v2.0 CDEs was October 18, 2023 – November 15, 2023. The final Mitochondrial Disease v2.0 CDE recommendations will be posted in March 2024.

Roster

Members of the Mitochondrial Disease v2.0 CDE Working Group by subgroup, current members of the Oversight Committee, the NIH Coordinating Team and the NINDS CDE Team are listed below. A roster spreadsheet can be downloaded from this link: Complete Version 2.0 Mitochondrial Disease CDE Working Group Roster

Complete Version 1.0 Mitochondrial Disease CDE Working Group Roster – Lists members of the Mitochondrial Disease v1.0 CDE Working Group by subgroup, previous members of the NIH Coordinating Team and the NINDS CDE Team.

Please see the Overview tab for additional project background and timeline information.

Oversight Committee Members

Oversight Committee Members

  • Michio Hirano, MD
    Columbia University Medical Center, New York, New York
    Co-Chair
  • Lynne A. Wolfe, MS, CRNP, BC
    National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, Maryland
    Co-Chair
  • Marni Falk, MD
    The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Russel Saneto, DO, PhD
    Seattle Children's Hospital, Seattle, Washington
  • John Shoffner, MD
    Atlanta, Georgia
  • Johan Van Hove, MD, PhD, MBA
    University of Colorado, Aurora, Colorado
  • Jerry Vockley, MD, PhD
    University of Pittsburgh, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
  • Philip Yeske, PhD
    United Mitochondrial Disease Foundation, Pittsburgh, Pennsylvania

Working Group Co-Chairs Version 2.0

Working Group Co-Chairs Version 2.0

  • Michio Hirano, MD
    Columbia University Medical Center, New York, New York
  • Lynne A. Wolfe, MS, CRNP, BC
    National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, Maryland

Audiology Outcomes Subgroup Version 2.0

Audiology Outcomes Subgroup Version 2.0

  • Carolyn Sue, MBBS, PhD
    Neuroscience Research Australia (NeuRA), Sydney, Australia
    Chair
  • Gregory Flamme, PhD
    Stephenson and Stephenson Research and Consulting (SASRAC), Forest Grove, Oregon
  • Margaret Kenna, MD, MPH
    Boston Children's Hospital, Boston, Massachusetts
  • Sharon Kujawa, PhD, CCC-A
    Harvard Medical School, Mass Eye and Ear, Boston, Massachusetts
  • Tomoko Makishima, MD, PhD
    The University of Texas Medical Branch, Galveston, Texas
  • Gayla L. Poling, PhD
    National Institute on Deafness and Other Communication Disorders (NIDCD), Bethesda, Maryland
  • Kelly Reavis, PhD, MPH, CCC-A
    National Center for Rehabilitative Auditory Research, Veterans Affairs Portland Health Care System, Portland, Oregon
  • Lisa Schimmenti, MD
    Mayo Clinical, Rochester, Minnesota
  • Christopher Zalewski, PhD
    National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), Bethesda, Maryland

Biomarkers Subgroup Version 2.0

Biomarkers Subgroup Version 2.0

  • Kimberly Chapman, MD, PhD
    Children's National Medical Center, Washington, District of Columbia
    Co-Chair
  • Fernando Scaglia, MD
    Baylor College of Medicine, Houston, Texas
    Co-Chair
  • Sarah Elsea, PhD
    Baylor College of Medicine, Houston, Texas
  • Devin Oglesbee, PhD
    Mayo Clinic, Rochester, Minnesota
  • Rohit Sharma, MD, PhD
    Massachusetts General Hospital, Boston, Massachusetts

Cognitive/Psychological Outcomes Subgroup Version 2.0

Cognitive/Psychological Outcomes Subgroup Version 2.0

  • Stephanie Assuras, PhD
    Columbia University Medical Center, New York, New York
    Chair
  • Lisa Emrick, MD
    Baylor College of Medicine, Houston, Texas
  • Emily Leaffer, PhD, MPH
    Blythedale Children's Hospital, Valhalla, New York
  • Rebecca Vaurio, PhD
    Children's of Minnesota, St. Paul, Minnesota

Endocrinology Subgroup Version 2.0

Endocrinology Subgroup Version 2.0

  • Shana McCormack, MD, MTR
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Chair
  • Jose E. Abdenur, MD
    Children's Hospital of Orange County, Orange, California
  • Timothy Cheetham, MBChB, MD
    Newcastle University, Newcastle upon Tyne, United Kingdom
  • Jane Estrella, MD, FRACP, MMed
    PathWest, Perth, Australia
  • Bret Goodpaster, PhD
    Advent Health Research Institute, Orlando, Florida
  • Jaclyn Tamaroff, MD
    Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
  • Fumihiko Urano, MD, PhD
    Washington University in St. Louis, St. Louis, Missouri
  • David Weber, MD
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Jarod Wong, MD
    University of Glasgow, Glasgow, United Kingdom

Exercise Physiology Subgroup Version 2.0

Exercise Physiology Subgroup Version 2.0

  • Tanja Taivassalo, PhD
    University of Florida, Gainesville, Florida
    Chair
  • Ronald Haller, MD
    University of Texas Southwestern Medical Center, Dallas, Texas
  • Russell Saneto, DO, PhD
    Seattle Children's Hospital, Seattle, Washington
  • Mark Tarnopolsky, MD, PhD
    McMaster University, Exerkine Corporation, Hamilton, Ontario, Canada
  • Zarazuela Zolkipli-Cunningham, MBChB, MRCP
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

General Medical/Neurological Assessments Subgroup Version 2.0

General Medical/Neurological Assessments Subgroup Version 2.0

  • Bruce H. Cohen, MD, FAAN
    Akron Children's Hospital, Akron, Ohio
    Chair
  • Richard Haas, MB, BChir
    University of California, San Diego, La Jolla, California
  • Margherita Milone, MD, PhD
    Mayo Clinic, Rochester, Minnesota
  • Ingrid Tein, MD, FRCPC
    University of Toronto, Toronto, Canada

Genetics Subgroup Version 2.0

Genetics Subgroup Version 2.0

  • William Copeland, PhD
    National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, North Carolina
    Chair
  • Valerio Carelli, MD, PhD
    University of Bologna School of Medicine, Bologna, Italy
  • Xiaowu Gai, PhD
    Keck School of Medicine of USC, Children's Hospital of Los Angeles, Los Angeles, California
  • Amel Karaa, MD
    Massachusetts General Hospital for Children, Boston, Massachusetts
  • Peter McGuire, MS, MBBCh
    National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, Maryland
  • Colleen Clarke Muraresku, MS, LCGC
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

GI/Hepatology and Nutrition Subgroup Version 2.0

GI/Hepatology and Nutrition Subgroup Version 2.0

  • Lindsay Burrage, MD, PhD
    Baylor College of Medicine, Houston, Texas
  • Michael Camilleri, MD
    Mayo Clinic, Rochester, Minnesota
  • Maria Mascarenhas, MBBS
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Hayat Mousa, MD
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Ronald Sokol, MD
    Children's Hospital Colorado, Aurora, Colorado
  • James Squires, MD, MS
    UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Imaging Subgroup Version 2.0

Imaging Subgroup Version 2.0

  • Amy Goldstein, MD
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Co-Chair
  • Andrea L. Gropman, MD
    Children's National Medical Center, Washington, District of Columbia
    Co-Chair
  • Cesar Alves, MD, PhD
    Boston Children's Hospital, Harvard University, Boston, Massachusetts
  • Raffaele Lodi, MD, PhD
    Bellaria Hospital, University of Bologna, Bologna, Italy
  • Arastoo Vossough, MD, PhD
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Matthew Whitehead, MD
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Ophthalmology Outcomes Subgroup Version 2.0

Ophthalmology Outcomes Subgroup Version 2.0

  • Wadih M. Zein, MD
    National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, Maryland
    Chair
  • Valerio Carelli, MD, PhD
    University of Bologna School of Medicine, Bologna, Italy
  • Kerry Goetz, MS
    National Eye Institute (NEI), National Institutes of Health, Bethesda, Maryland
  • Jimmy Le, ScD
    National Eye Institute (NEI), National Institutes of Health, Bethesda, Maryland
  • David A. Mackey, MBBS, MD
    Lions Eye Institute, Nedlands, Australia

Patient Reported Outcomes/Quality of Life/Fatigue Subgroup Version 2.0

Patient Reported Outcomes/Quality of Life/Fatigue Subgroup Version 2.0

  • Mary Kay Koenig, MD
    University of Texas Health Science Center, Houston, Texas
    Co-Chair
  • Sumit Parikh, MD
    Cleveland Clinic, Cleveland, Ohio
    Co-Chair
  • Michelangelo Mancuso, MD, PhD
    University of Pisa, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Cristy Balcells, RN, MSN
    UCB, Asheville, North Carolina
  • Amy Goldstein, MD
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Grainne Gorman, MRCP, PhD
    Newcastle University, Newcastle upon Tyne, United Kingdom
  • Amel Karaa, MD
    Massachusetts General Hospital, Boston, Massachusetts
  • Cornelia Kornblum, MD
    University Hospital Bonn, Bonn, Germany
  • Philip Yeske, PhD
    United Mitochondrial Disease Foundation, Pittsburgh, Pennsylvania

NIH Coordinating Team

NIH Coordinating Team

  • Adam Hartman, MD, FAAP, FANA, FAES
    National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland
  • Peter McGuire, MS, MBBCh
    National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, Maryland
  • Douglas Meinecke, PhD
    National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Bethesda, Maryland
  • Lynne A. Wolfe, MS, CRNP, BC
    National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, Maryland

NINDS CDE Team

NINDS CDE Team

  • Adam Hartman, MD, FAAP, FANA, FAES
    National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland
  • M. Carolina Mendoza-Puccini, MD
    NINDS CDE Program Director, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland
  • Alva Recinos, MD
    National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland
  • Sherita Ala'i Hansen, MS (Until 2018)
    The Emmes Company, LLC, Rockville, Maryland
  • Clara Aman, MPH
    The Emmes Company, LLC, Rockville, Maryland
  • Damon Collie, MSHS
    The Emmes Company, LLC, Rockville, Maryland
  • Becky Dowd, MSCLS
    The Emmes Company, LLC, Rockville, Maryland
  • Ilar Edun, BA (Until 2020)
    The Emmes Company, LLC, Rockville, Maryland
  • Joy Esterlitz, MS (Until 2020)
    The Emmes Company, LLC, Rockville, Maryland
  • Elias R. Feldman (Until 2015)
    The Emmes Company, LLC, Rockville, Maryland
  • Robin Feldman, BS, MBA
    The Emmes Company, LLC, Rockville, Maryland
  • Andy Franklin, BA
    The Emmes Company, LLC, Rockville, Maryland
  • Ayanna Garland (Until 2014)
    The Emmes Company, LLC, Rockville, Maryland
  • Katelyn Gay, BS
    The Emmes Company, LLC, Rockville, Maryland
  • Marybeth Montoro, MPH, CPH (Until 2015)
    The Emmes Company, LLC, Rockville, Maryland
  • Divya Nigam, BS (Until 2018)
    The Emmes Company, LLC, Rockville, Maryland
  • Shola Ogbodo, BS
    The Emmes Company, LLC, Rockville, Maryland
  • Muniza Sheikh, MS, MBA
    The Emmes Company, LLC, Rockville, Maryland
  • Ian Spector, BS, MPS
    The Emmes Company, LLC, Rockville, Maryland
  • Amanda Suller, BS (Until 2015)
    The Emmes Company, LLC, Rockville, Maryland

Updates

Please see attached revision history document. Please contact NINDSCDE@emmes.com if you require further information or have any questions about the revision history.

Mitochondrial CDE Revision History Document